Evidence map›Paper›PMID 27766663›Full record

ArticleAmerican journal of hematology2017

Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer.

Yan Dai, Jose Sangerman, Mehdi Nouraie, Aidan D Faller, Patricia Oneal, Angela Rock, Oluwakemi Owoyemi, Xiaomei Niu, Sergei Nekhai, Dashmeet Maharaj and 4 more

Registry-linked trialAbstract readLetter
In one paragraph

Article in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04432623 (A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04432623 phase1 / phase2enrolling by invitationnot on this mapstarted 2020, after this paper: background citation

A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease

TypeinterventionalSponsorPhoenicia BioScienceRan2020 to 2026Enrolled36ConditionsBeta Thalassemia Intermedia, Sickle Cell DiseaseArmsBenserazide Only Product
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yan DaiCancer Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Jose SangermanHemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, Massachusetts.
Mehdi NouraieDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Aidan D FallerHemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, Massachusetts.
Patricia OnealCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Angela RockCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Oluwakemi OwoyemiCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Xiaomei NiuCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Sergei NekhaiCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Dashmeet MaharajHemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, Massachusetts.
Shauiying CuiHematology Oncology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Robert TaylorCenter for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia.
Martin SteinbergHematology Oncology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Susan PerrineCancer Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Funding

PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
NOVEL GLOBIN GENE MODULATORSR01DK052962 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PERRINE, SUSAN PARK · 1998 to 2016
$4.2M
Development of a clinical hemoglobin modulatorR42HL110727 · NHLBI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2014 to 2015
$1000k
Next Generation Therapeutics for HemoglobinopathiesR41HL108516 · NHLBI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2012 to 2012
$491k
NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R41 HL108516NHLBI NIH HHS R42 HL110727NIDDK NIH HHS R01 DK052962NIMHD NIH HHS G12 MD007597
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAnemia, Sickle CellErythrocytes, AbnormalFemaleFetal GlobulinsHumansHydroxyureaMaleMiddle AgedFetal GlobulinsHydroxyurea

Identifiers

PMID27766663
PMCPMC5167623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.